- Home
- ENTA vs NAN Comparison
ENTA vs NAN Comparison
Compare ENTA & NAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- NAN
- Stock Information
- Founded
- ENTA 1995
- NAN 1999
- Country
- ENTA United States
- NAN United States
- Employees
- ENTA N/A
- NAN N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- NAN Investment Managers
- Sector
- ENTA Health Care
- NAN Finance
- Exchange
- ENTA Nasdaq
- NAN Nasdaq
- Market Cap
- ENTA 316.2M
- NAN 357.9M
- IPO Year
- ENTA 2013
- NAN N/A
- Fundamental
- Price
- ENTA $12.65
- NAN $11.50
- Analyst Decision
- ENTA Strong Buy
- NAN
- Analyst Count
- ENTA 6
- NAN 0
- Target Price
- ENTA $20.33
- NAN N/A
- AVG Volume (30 Days)
- ENTA 387.8K
- NAN 74.6K
- Earning Date
- ENTA 11-17-2025
- NAN 01-01-0001
- Dividend Yield
- ENTA N/A
- NAN 4.37%
- EPS Growth
- ENTA N/A
- NAN N/A
- EPS
- ENTA N/A
- NAN N/A
- Revenue
- ENTA $65,324,000.00
- NAN N/A
- Revenue This Year
- ENTA $2.13
- NAN N/A
- Revenue Next Year
- ENTA $2.74
- NAN N/A
- P/E Ratio
- ENTA N/A
- NAN N/A
- Revenue Growth
- ENTA N/A
- NAN N/A
- 52 Week Low
- ENTA $4.09
- NAN $9.11
- 52 Week High
- ENTA $15.34
- NAN $11.34
- Technical
- Relative Strength Index (RSI)
- ENTA 66.08
- NAN 47.35
- Support Level
- ENTA $11.89
- NAN $11.45
- Resistance Level
- ENTA $13.00
- NAN $11.56
- Average True Range (ATR)
- ENTA 0.83
- NAN 0.07
- MACD
- ENTA 0.09
- NAN -0.01
- Stochastic Oscillator
- ENTA 80.78
- NAN 29.23
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About NAN Nuveen New York Quality Municipal Income Fund
Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal, New York State and New York City income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.